Following on from information provided to NICE by the company in February 2021, the appraisal of Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 2702
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Note added to the project documents |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2021, the appraisal of Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 26 February 2021 | Suspended. Topic is suspended |
| 26 February 2021 | Note added to the project documents |
| 24 January 2020 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual